New Saidal Plant Aims to Reduce Antibiotic Imports

Saidal Group's CEO, Younes Bouarara, recently visited the ongoing construction of a raw material factory for antibiotics in the Hurbil municipality, Médéa province. This visit underscored the strategic importance of the project, which is designed to bolster national pharmaceutical sovereignty and significantly decrease Algeria's reliance on imported pharmaceutical products, particularly antibiotics. The initiative is a key component of national efforts to develop a robust local pharmaceutical industry.

The factory's development aligns with Saidal Group's overarching strategy to expand its production capabilities, gradually shifting from solely meeting domestic market demands to enhancing its presence in international markets. Algeria currently incurs an annual import bill of 75.4 billion Algerian Dinars for antibiotics. Upon becoming operational, the new facility is expected to address a substantial portion of these import needs.

The successful completion and operation of this unit are projected to elevate national production capacities for antibiotics and their associated raw materials. This will solidify Saidal Group's position as a strategic industrial contributor in the pharmaceutical sector. Furthermore, the project is anticipated to contribute to an increase in Saidal's turnover, potentially reaching levels approaching one billion US dollars. Saidal's dedication to expediting and overseeing such strategic projects directly supports national directives, including those from President Abdelmadjid Tebboune, aimed at fostering a strong domestic drug industry and ensuring the country's health and pharmaceutical security.